加速康复外科与常规护理在腹腔镜远端胃癌根治术中短期结局的随机对照试验(GISSG1901)
该随机、多中心、非盲试验纳入400例cT2-4aN0-3M0胃腺癌患者,比较ERAS与常规方案在腹腔镜远端胃切除术后的短期结局。ERAS组出院许可日、术后住院时间、首次排气/进流食/下床时间及医疗费用均优于常规组,且辅助化疗启动更早;两组并发症、死亡率和再入院率无显著差异。
要点
- ERAS可缩短腹腔镜远端胃切除术后住院时间并降低医疗费用,不增加并发症和再入院。
- ERAS组术后首次排气、进流食和下床活动时间均显著早于常规组。
- ERAS组辅助化疗启动时间更早(29天 vs 32天,P=0.035)。
核心结论
- ERAS方案在腹腔镜远端胃切除术后提供更快的康复、更短的术后住院时间和更低的医疗费用,且不增加并发症和再入院率。
- ERAS组的加速康复使辅助化疗能够更早启动。
研究设计与样本
- 随机、多中心、非盲试验,纳入组织学确诊的cT2-4aN0-3M0胃腺癌患者。
- 2019年4月至2020年5月连续入组400例,随机分配至ERAS组(n=200)或常规组(n=200)。
- 排除未手术或未行胃切除的患者后,最终分析370例。
主要发现
- 常规组允许出院日和术后住院时间均显著长于ERAS组(6.96 vs 5.83天,P<0.001;8.85 vs 7.27天,P<0.001)。
- 常规组首次排气、进流食和下床活动时间均显著长于ERAS组(3.37 vs 2.52天,P<0.001;3.09 vs 1.13天,P<0.001;2.85 vs 1.38天,P<0.001)。
- 常规组医疗费用显著高于ERAS组(6826 vs 6328 $,P=0.027)。
- ERAS组辅助化疗启动更早(29 vs 32天,P=0.035)。
- 两组术后并发症、死亡率和再入院率无显著差异;ERAS组术后第3天降钙素原和C反应蛋白显著更低,术后第5天血红蛋白显著更高。
临床怎么用
- 在腹腔镜远端胃切除术围术期可应用ERAS方案以加速康复、缩短住院时间并降低费用。
- ERAS方案不增加并发症和再入院风险,且有助于提早启动辅助化疗。
局限性
- 研究为非盲设计。
- 排除未手术或未行胃切除的患者后最终分析370例,与随机入组400例存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to compare the effects of ERAS and conventional programs on short-term outcomes after LDG. SUMMARY OF BACKGROUND DATA: Currently, the ERAS program is broadly applied in surgical areas. Although several benefits of LDG with the ERAS program have been covered, high-level evidence is still limited, specifically in advanced gastric cancer. METHODS: The present study was designed as a randomized, multicenter, unblinded trial. The enrollment criteria included histologically confirmed cT2-4aN0-3M0 gastric adenocarcinoma. Postoperative complications, mortality, readmission, medical costs, recovery, and laboratory outcomes were compared between the ERAS and conventional groups. RESULTS: Between April 2019 and May 2020, 400 consecutive patients who met the enrollment criteria were enrolled. They were randomly allocated to either the ERAS group (n = 200) or the conventional group (n = 200). After excluding patients who did not undergo surgery or gastrectomy, 370 patients were analyzed. The patient demographic characteristics were not different between the 2 groups. The conventional group had a significantly longer allowed day of discharge and postoperative hospital stay (6.96 vs 5.83 days, P < 0.001; 8.85 vs 7.27 days, P < 0.001); a longer time to first flatus, liquid intake and ambulation (3.37 vs 2.52 days, P < 0.001; 3.09 vs 1.13 days, P < 0.001; 2.85 vs 1.38 days, P < 0.001, respectively); and higher medical costs (6826 vs 6328 $, P = 0.027) than the ERAS group. Additionally, patients in the ERAS group were more likely to initiate adjuvant chemotherapy earlier (29 vs 32 days, P = 0.035). There was no significant difference in postoperative complications or in the mortality or readmission rates. Regarding laboratory outcomes, the procalcitonin and C-reactive protein levels on postoperative day 3 were significantly lower and the hemoglobin levels on postoperative day 5 were significantly higher in the ERAS group than in the conventional group. CONCLUSION: The ERAS program provides a faster recovery, a shorter postoperative hospitalization length, and lower medical costs after LDG without increasing complication and readmission rates. Moreover, enhanced recovery in the ERAS group enables early initiation of adjuvant chemotherapy.
引用
- Tian Y, Cao S, Liu X, et al. Randomized Controlled Trial Comparing the Short-term Outcomes of Enhanced Recovery After Surgery and Conventional Care in Laparoscopic Distal Gastrectomy (GISSG1901). Ann Surg. 2022. PMID: 33856385. doi:10.1097/SLA.0000000000004908
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。